Scientific Papers

Novel molecular typing reveals the risk of recurrence in patients with early-stage papillary thyroid cancer | Thyroid Research

Description of Image

  • Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–99.

    Article 
    MathSciNet 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058–69.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huang K, Gao N, Bian D, Zhai Q, Yang P, Zhang Y. Associations of BRAF V600E, clinical pathology and imaging factors with the recurrence rate of papillary thyroid microcarcinoma. Exp Ther Med. 2020;20(6):243.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • van Velsen EFS, Stegenga MT, van Kemenade FJ, Kam BLR, van Ginhoven TM, Visser WE, Peeters RP. Comparing the Prognostic Value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System between Papillary and follicular thyroid Cancer. Thyroid. 2018;28(8):976–81.

    Article 
    PubMed 

    Google Scholar
     

  • Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA. Exploring the relationship between patient age and Cancer-specific survival in papillary thyroid Cancer: Rethinking Current Staging systems. J Clin Oncol. 2016;34(36):4415–20.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Thewjitcharoen Y, Chatchomchuan W, Karndumri K, Porramatikul S, Krittiyawong S, Wanothayaroj E, Butadej S, Nakasatien S, Veerasomboonsin V, Kanchanapituk A, et al. Impacts of the American Joint Committee on Cancer (AJCC) 8(th) edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients. Heliyon. 2021;7(3):e06624.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, Feinmesser R, Peretz H, Shimon I, Lapidot M. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 2007, 17(6):549–556.

  • Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH. Community of Population-based Regional Cancer R: Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017;49(2):292–305.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest. 2016;126(3):1052–66.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Read ML, Fong JC, Modasia B, Fletcher A, Imruetaicharoenchoke W, Thompson RJ, Nieto H, Reynolds JJ, Bacon A, Mallick U, et al. Elevated PTTG and PBF predicts poor patient outcome and modulates DNA damage response genes in thyroid cancer. Oncogene. 2017;36(37):5296–308.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Read ML, Seed RI, Fong JC, Modasia B, Ryan GA, Watkins RJ, Gagliano T, Smith VE, Stratford AL, Kwan PK, et al. The PTTG1-binding factor (PBF/PTTG1IP) regulates p53 activity in thyroid cells. Endocrinology. 2014;155(4):1222–34.

    Article 
    PubMed 

    Google Scholar
     

  • Nieto HR, Thornton CEM, Brookes K, Nobre de Menezes A, Fletcher A, Alshahrani M, Kocbiyik M, Sharma N, Boelaert K, Cazier JB, et al. Recurrence of papillary thyroid Cancer: a systematic Appraisal of Risk factors. J Clin Endocrinol Metab. 2022;107(5):1392–406.

    Article 
    PubMed 

    Google Scholar
     

  • Read ML, Brookes K, Thornton CEM, Fletcher A, Nieto HR, Alshahrani M, Khan R, Borges de Souza P, Zha L, Webster JRM, et al. Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter. Cell Chem Biol. 2022;29(3):502–516e507.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Read ML, Brookes K, Zha L, Manivannan S, Kim J, Kocbiyik M, Fletcher A, Gorvin CM, Firth G, Fruhwirth GO et al. Combined Vorinostat and Chloroquine inhibit Sodium Iodide Symporter endocytosis and enhance Radionuclide Uptake in vivo. Clin Cancer Res 2023.

  • Yi L, Wu G, Guo L, Zou X, Huang P. Comprehensive Analysis of the PD-L1 and Immune infiltrates of m(6)a RNA methylation regulators in Head and Neck squamous cell carcinoma. Mol Ther Nucleic Acids. 2020;21:299–314.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu Z, Zhao Q, Zuo ZX, Yuan SQ, Yu K, Zhang Q, Zhang X, Sheng H, Ju HQ, Cheng H et al. Systematic Analysis of the Aberrances and Functional Implications of Ferroptosis in Cancer. iScience 2020, 23(7):101302.

  • Li Y, Xiao J, Bai J, Tian Y, Qu Y, Chen X, Wang Q, Li X, Zhang Y, Xu J. Molecular characterization and clinical relevance of m(6)a regulators across 33 cancer types. Mol Cancer. 2019;18(1):137.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang Z, Lin E, Zhuang H, Xie L, Feng X, Liu J, Yu Y. Construction of a novel gene-based model for prognosis prediction of clear cell renal cell carcinoma. Cancer Cell Int. 2020;20:27.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li B, Cui Y, Nambiar DK, Sunwoo JB, Li R. The Immune subtypes and Landscape of squamous cell carcinoma. Clin Cancer Res. 2019;25(12):3528–37.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Karasinska JM, Topham JT, Kalloger SE, Jang GH, Denroche RE, Culibrk L, Williamson LM, Wong HL, Lee MKC, O’Kane GM, et al. Altered gene expression along the glycolysis-cholesterol synthesis Axis is Associated with Outcome in Pancreatic Cancer. Clin Cancer Res. 2020;26(1):135–46.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Huang Y, Qu S, Zhu G, Wang F, Liu R, Shen X, Viola D, Elisei R, Puxeddu E, Fugazzola L, et al. BRAF V600E mutation-assisted risk stratification of Solitary Intrathyroidal Papillary thyroid Cancer for Precision Treatment. J Natl Cancer Inst. 2018;110(4):362–70.

    Article 
    PubMed 

    Google Scholar
     

  • Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–62.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–62.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9(12):886–96.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sancar A, Lindsey-Boltz LA, Gaddameedhi S, Selby CP, Ye R, Chiou YY, Kemp MG, Hu J, Lee JH, Ozturk N. Circadian clock, cancer, and chemotherapy. Biochemistry. 2015;54(2):110–23.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jiang HY, Ning G, Wang YS, Lv WB. Ahypoxia-related signature enhances the prediction of the prognosis in hepatocellular carcinoma patients and correlates with sorafenib treatment response. Am J Transl Res. 2020;12(12):7762–81.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenfuhrer J, Oster H, Hengstler JG. Loss of circadian clock gene expression is associated with tumor progression in breast cancer. Cell Cycle. 2014;13(20):3282–91.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett. 2014;342(1):9–18.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375–82.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bellet MM, Stincardini C, Costantini C, Gargaro M, Pieroni S, Castelli M, Piobbico D, Sassone-Corsi P, Della-Fazia MA, Romani L et al. The circadian protein PER1 modulates the Cellular response to Anticancer treatments. Int J Mol Sci 2021, 22(6).

  • Amangyeld T, Shin YK, Lee M, Kwon B, Seo YS. Human MUS81-EME2 can cleave a variety of DNA structures including intact Holliday junction and nicked duplex. Nucleic Acids Res. 2014;42(9):5846–62.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Calzetta NL, Gonzalez Besteiro MA, Gottifredi V. Mus81-Eme1-dependent aberrant processing of DNA replication intermediates in mitosis impairs genome integrity. Sci Adv 2020, 6(50).

  • Pepe A, West SC. MUS81-EME2 promotes replication fork restart. Cell Rep. 2014;7(4):1048–55.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kurashima K, Sekimoto T, Oda T, Kawabata T, Hanaoka F, Yamashita T. Poleta, a Y-family translesion synthesis polymerase, promotes cellular tolerance of myc-induced replication stress. J Cell Sci 2018, 131(12).

  • Wu X, Spitz MR, Lee JJ, Lippman SM, Ye Y, Yang H, Khuri FR, Kim E, Gu J, Lotan R, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009;2(7):617–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Long G, Ouyang W, Zhang Y, Sun G, Gan J, Hu Z, Li H. Identification of a DNA repair gene signature and establishment of a Prognostic Nomogram Predicting biochemical-recurrence-free survival of prostate Cancer. Front Mol Biosci. 2021;8:608369.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Weis E, Schoen H, Victor A, Spix C, Ludwig M, Schneider-Raetzke B, Kohlschmidt N, Bartsch O, Gerhold-Ay A, Boehm N, et al. Reduced mRNA and protein expression of the genomic caretaker RAD9A in primary fibroblasts of individuals with childhood and independent second cancer. PLoS ONE. 2011;6(10):e25750.

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Description of Image

    Source link